New hope for ovarian cancer patients when standard drugs fail

This study is testing whether two different drug combinations can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer that has continued to grow despite previous treatment with a specific type of targeted therapy called a PARP inhibitor. It will enroll about 96 women to receive either one experimental drug alone or that drug combined with another. The main goal is to see if these treatments can shrink tumors or stop their growth.